Slide 1: Investor Presentation March 2019
pro+medicus OUR SUPPORT. YOUR SUCCESS. INVESTOR PRESENTATION MARCH 2019 Lf VISAGE IMAGING’
Slide 2: Pro Medicus (ASX:PME)
y vv PRO MEDICUS (ASX:PME) Healthcare IT company specializing in Enterprise Imaging and 4 Radiology Information System (RIS) software. Leading edge products, growing global presence. @ VISAGE RIS EU HQ/R&D Berlin GmbH U.S. HO San Diego CA 7" | = —%y OUP Ho r¢ eR ©. NN A * founsupront your success VI
Slide 3: Visage RIS and Visage 7 OEM Product Suite
VISAGE RIS ©) ASX:PME pro+medicus.net @B VISAGE? Pd | OEM VISAGE 7 OEM PRODUCT SUITE prosmedicu % ners ie, Visace IMAGING:
Slide 4: Results HY 2019
RESULTS HY 2019 $9.082M $9.234M 51.8% Profit . % ) Underlying watt | ($) se, (%) mn” om (<8) | $24.735M $0.035 Cash ® Company Strong (al) Fully franked reserves debt balance interim free sheet dividend + Special advance dividend of $0.025 fully franked & VISAGE TMAGING"
Slide 5: In Review HY 2019
y AA 4 IN REVIEW HY 2019 arle PARTNERS zi CLINIC aS lewHaven svarle =| PARTNERS EES Gp nee ‘ill —_) $5M $27M $3M New New German Govt. Hospital On/Ahead Increased Strong Contract Contract Contract Extension of schedule market lead growth + + + + + + US. JULY 2018 NOVEMBER 2018 DECEMBER 2018 IMPLEMENT
Slide 6: HY 2019 Revenue Split
A o> HY 2019 Revenue Split ) A A j A $30,000,000 $25,000,000 $20,000,000 $15,000,000 $10,000,000 $5,000,000 GExam/licence revenue*** 1H v 2H Revenue split - Reinstated for AASB 15 OSupport/baseline r evenue*** Capital revenue (net of hardware) ***Recurring revenue O Professional Services (new revenu
Slide 7: Professional Services
A VV PROFESSIONAL SERVICES Vv ¢ Project planning, training & implementation -—————— [ol * Revenue spread over the length of the contract Q A - new accounting standards (AASB 15) L ° Recurring in nature ~ 10% contract value oo i } e Will decrease as a % of total revenue as exam 0 y (transaction) reve
Slide 8: Exam (Transaction) Revenue
YY EXAM (TRANSACTION) REVENUE / ‘ 9 ¢ Recurring in nature ° Increased by 31% from 2H18 to 1H19 * Growth to continue in FY 2019 onwards (Mayo, Yale & others) * Growth from existing clients (organic and M&A) plus new clients * Step up in FY 2020 with Partners Healthcare A * Further upside with adoptio
Slide 9: Operational (Transaction) Model
y OPERATONAL (TRANSACTION) MODEL Used in vast majority of US contracts Delivered as SaaS model Now used in RIS contracts in AUS Model based on quaranteed transaction minimums Forward revenue > AS160M/5 years* Upside as client examination volumes grow Annuity style revenue stream — greater predictabi
Slide 10: Operating Leverage
OPERATING LEVERAGE ¢ Highly scalable offering ed * No capex (HW) - SW only model S ° Training & Installation - charged as professional | services s ¢ Relatively fixed cost base * High operating leverage ¢ Margin continues to grow as footprint increases te $$ prosmedicus | 4% founsupront your succes
Slide 11: Margin Expansion
MARGIN EXPANSION EBIT Margins | = FY-14 FY-15 FY-16 FY-17 FY-18 es te % vi IMAGING"
Slide 12: Visage RIS
@ VISAGERIS TECHNOLOGIST DOCTOR TRANSCRIPTIONIST. SEARCH CLAIMING — SETUP. Recent|¥ Dr RSimpson |v /+ ‘Appointments Northern Book ‘Visage General Hospital 4 Tue, 17-0cr201 MTP” @ Patient © Procedure [Cancelled Blocked Visage Xray ~ Visage US Room ~ Visage US Room 2 ~ ssn (Visage US Room3 + Visage Ma
Slide 13: Visage RIS
y 4 VISAGE RIS ye VE) Long term (5 year) contracts with Primary Healthcare and @ VISAGE RIS |-MED, the 2 biggest radiology providers in AUS Radiology smprchensive care. Uncompromising quality. Combined additional revenue of $4.4M pa once fully deployed cay saa “MED Network Rollouts progressing well
Slide 14: Leading Edge Platform
LEADING EDGE PLATFORM Visage Imaging continues to be #1 in Speed, Functionality and Scalability. SPEED FUNCTIONALITY SCALABILITY prosmedicus % SUR suron Youn sucess VISAGE TMAGING’
Slide 15: North American Market
NORTH AMERICAN MARKET VISAGE IMAGING’ ¢ PACS market estimated at > US $2B pa and growing * Expanding into Enterprise Imaging ¢ Paradigm shift to modular, best-of-breed approach ¢ Market fragmented — in process of consolidating ¢ VISAGE 7? - proven, market leading technology ¢ Rapidly growing PME foo
Slide 16: Massive Data Explosion
MASSIVE DATA EXPLOSION ¢ High density Multi-slice CT - 10,000+ images ¢ HD Breast Tomosynthesis - 6 GB+ ¢ (Optoacoustic breast ultrasound - 10+ GB ¢ Total Body PET Scan - 10+ GB ¢ 7T MRI - much larger than 3T & VISAGE TMAGING"
Slide 17: Electronic Health Record (EHR)
ELECTRONIC HEALTH RECORD (EHR) ¢ Mandated in US Hospitals by end of 2018 * Consolidates all hospitals data - clinical and financial ° 90% of EHR is imaging data (by volume) ¢ Driving adoption of VNA ¢ Need fora single viewer for all images prosmedicu & ‘OUR SUPPORT. YOUR SUCCESS. VISAGE. TMAGING’
Slide 18: Solution: Visage 7 Streaming Technology
A YY SOLUTION: 4 «& VISAGE 7? Streaming Technology RADIOLOGIST/CLINICIAN 7 BACKEND RENDER %) SERVER SERVER 7 A prosmedicus 4% founsupront your success VISAGE IMAGING’
Slide 19: Partners Healthcare
PARTNERS HEALTHCARE Largest health system in Massachusetts Massachusetts General Hospital ranked (#4) and Brigham and Women's Hospital (#20) best hospital in US Top two teaching hospitals for Harvard Medical School Leader in biomedical and data science research — renowned MGH & BWH Center for Clinic
Slide 20: Partners Healthcare (cont.)
PARTNERS HEALTHCARE (cont. ) ¢ 7-year, $27M deal, transaction-based licensing model ¢ Largest contract in the history of PME ¢ VISAGE ? cornerstone of the Partners Radiology Enterprise Platform (PREP) ¢ Transformational - a key component of Partners 2.0 initiative prosmedicu % ners ie, Visace IMAGIN
Slide 21: Partners Healthcare (cont.)
PARTNERS HEALTHCARE (cont. ) Phase 1 ¢ Massachusetts General Hospital and Brigham and Women's Hospital ¢ Underway, with Go-Live planned for late Q4 FY19 Phase 2 ¢ Other Partners HealthCare network hospitals * |mplementation following completion of Phase 1 prosmedicu & VISAGE TMAGING'
Slide 22: Other Sales
A , VY OTHER SALES Carle Foundation - regional health system in Urbana IL 95M - 7 year transaction based deal VISN 23 - 5 year contract renewal Combined - deals worth $9M over 7 years prosmedicus | 4% founsupront your success VISAGE IMAGING’
Slide 23: Implementations
4 VV IMPLEMENTATIONS On/Ahead Continues Completed under 25% of Continues of schedule to deliver the industry norm to deliver All Implementations Fast Track Methodology Large Scale Projects Huge Savings to the Client Frees Up Staff Reduced Key Differentiator Barrier to Change Ability to do Other Jobs
Slide 24: Visage - Proven ROI
A & ry VISAGE - PROVEN ROI Visace IMAGING’ >. Significant IT & Unparalleled Increase in Greater Clinical Infrastructure Savings Radiologist Efficiency Accuracy Vv Improved Physician Delivers Superior y Engagement Value Proposition prosmedicus | 4% founsupront your success VISAGE IMAGING’
Slide 25: Visage - Proven ROI - Clinical
VISAGE — PROVEN ROI - CLINICAL ¢ Child presents with severe headaches ¢ (T: aneurysms requiring emergency intervention ¢ No time to wait for tech or 3D lab post-processing ¢ MRA/VRA performed on-the-fly in VISAGE 7 prosmedicu % ners ie, Visace IMAGING:
Slide 26: Visage
a VISAGE - VISAGE TMAGING’ me omer tet ow itt A GOES A 7 prosmedicus 4 ‘oun suPpoRT.vour sucess VISAGE TMAGING®
Slide 27: Visage - Proven ROI - Financial
os VISAGE - PROVEN ROI - FINANCIAL VISAGE TMAGING’ Radiologist Productivity and Turn-Around Time Data Analytics STAT exams - 30.4% Radiologist turn-around-time improvement (Enterprise) Turn Around Time and Exam Volume - Stroke Median Rad TAT (min) o Ee 3 ° > = o x wi . “ prosmedicus ) ‘un suppor. vo
Slide 28: Visage - Proven ROI - Financial
VISAGE - PROVEN ROI — FINANCIAL VISAGE TMAGING" ' CT Utilisation Growth at Visage Customer Reading “Thins” - 23% Growth 10000 9000 8000 7000 Vv 6000 . 5000 A A 4000 3000 4 7 2000 A 1000 —_" 0 prosmedicus 4% founsupront your success VISAGE IMAGING’
Slide 29: Growth Strategy
7 vv GROWTH STRATEGY y Transaction growth A from existing clients / Expand footprint - New clients New product offerings A for existing clients VA Extend to other 7 EY geographical markets J Leverage R&D capability VV to introduce next generation products & VISAGE TMAGING"
Slide 30: New Products: Visage 7 Open Archive
A VV NEW PRODUCTS VISAGE ? OPEN ARCHIVE ¢ Same highly scalable enterprise imaging platform used in VISAGE 7 ¢ Modular design - interoperable in complex environments ¢ — Enables Visage to offer choice of deconstructed or single vendor solutions Vv ) %) ¢ Well placed for North American : Pe) | y V arc
Slide 31: Mercy
A, VV MERCY VISAGE ? OPEN ARCHIVE ° $15M-7 year deal ¢ Mercy to standardize on VISAGE 7 Open Archive across its diagnostic imaging business ° Over 28M diagnostic imaging exams migrated to VISAGE Open Archive V A A © Go live early 04 FY2019 ; A VV * Once completed - one of the largest © medical imagi
Slide 32: New Products Enterprise Imaging
VV NEW PRODUCTS ENTERPRISE IMAGING VISAGE 7 Al ¢ — Single viewer for ALLimages in the medical record (EMR) * — Radiology/Cardiology (DICOM format) ENCOUNTER ¢ Non-radiology- reflected light - v hi-res photos & videos 7 a ¢ VISAGE 7 technology ideally suited / A * Increases Visage value proposition o
Slide 33: Enterprise Imaging
ENTERPRISE IMAGING
Slide 34: Prospects
6) Prospects V Network Effect A Opportunities A At various stages of the cycle From recent high profile wins Increasing number coming to market Pipeline Robust In terms of quality and quantity of opportunities prosmedicus | % founsupront your success VISAGE IMAGING’
Slide 35: Artificial Intelligence Visage AI
4 vv ARTIFICIAL INTELLIGENCE 6 VISAGE ‘Al ¢ Healthcare imaging ideally suited to Al ¢ Visage well positioned to take advantage of this emerging technology Vv ¢ Advanced image processing in © | A healthcare is “in our DNA” ¢ VISAGE ? architecture uses GPU -~ 4 A technology (6 4) ZF ER Ss) o4 7 © Grow
Slide 36: Artificial Intelligence (cont.)
ARTIFICIAL INTELLIGENCE (cont. ) ¢ "In product” Al - automated high-end functions within VISAGE 7 e VISAGE 7 Al single visualization — platform for both the clinical AND research environments ¢ VISAGE 7 Al- Open platform enables integration of 3 party algorithms ¢ — Platform for possible future Visa
Slide 37: Summary
SUMMARY ¢ Growing North American footprint ¢ Transaction revenue up 31% compared to prior 6 month period ¢ Market leading technologies ¢ Proven implementation & support capability * Unparalleled value proposition (Clinical and Financial ROI) ¢ 1% Jarge scale VISAGE 7 Open Archive in U.S. ¢ New Produ
Slide 38: a) f=) > << = <o - kt
a) f=) > << = <o - kt